Treatment of congestive heart failure -: Guidelines for the primary care physician and the heart failure specialist

被引：48

作者：

Gomberg-Maitland, M ^{[1
]}

Baran, DA ^{[1
]}

Fuster, V ^{[1
]}

机构：

[1] CUNY, Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, Dept Cardiol, New York, NY 10029 USA

来源：

ARCHIVES OF INTERNAL MEDICINE | 2001年 / 161卷 / 03期

关键词：

D O I：

10.1001/archinte.161.3.342

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

During the past 10 years, the philosophy of heart failure treatment has evolved from symptom control to a combined prevention and symptom-management strategy. Recent clinical trials have proved that early detection can delay progression. Treatment of asymptomatic left ventricular dysfunction is as important as treatment of symptomatic disease. The purpose of this review is to simplify recent guidelines for pharmacological management of chronic systolic heart failure for the primary care physician and the heart failure specialist. Early recognition and prevention therapies, combined with lifestyle modification, are essential in the treatment of heart Failure. Therapy with angiotensin-converting enzyme inhibitors, beta -blockers, and diuretics is now standard. Digoxin is added to improve clinical symptoms, especially in patients with atrial fibrillation. Aldosterone antagonists may be recommended in select patients with stable New York Heart Association class III or IV heart failure. If angiotensin-converting enzyme inhibitors are not tolerated, angiotensin receptor blockers, hydralazine hydrochloride, and isosorbide dinitrate are recommended. The data on antiarrhythmic and anticoagulation therapies are inconclusive.

引用

页码：342 / 352

页数：11

共 121 条

[11]

BRISTOW MR, 1996, CIRCULATION, V94, P644

[12] β-blocker therapy for heart failure -: The evidence is in, now the work begins [J].

Califf, RM ;

O'Connor, CM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10) :1335-1337

[13]

*CARD, 2000, WARF ASP STUD HEART

[14]

CLARKE KW, 1994, BRIT HEART J, V71, P584

[15]

Cleland J G, 1998, Lancet, V352 Suppl 1, pSI1, DOI 10.1016/S0140-6736(98)90011-3

[16] SODIUM AND WATER-BALANCE IN CHRONIC CONGESTIVE-HEART-FAILURE [J].

CODY, RJ ;

COVIT, AB ;

SCHAER, GL ;

LARAGH, JH ;

SEALEY, JE ;

FELDSCHUH, J .

JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (05) :1441-1452

[17] EFFECT OF VASODILATOR THERAPY ON MORTALITY IN CHRONIC CONGESTIVE-HEART-FAILURE - RESULTS OF A VETERANS-ADMINISTRATION COOPERATIVE STUDY [J].

COHN, JN ;

ARCHIBALD, DG ;

ZIESCHE, S ;

FRANCIOSA, JA ;

HARSTON, WE ;

TRISTANI, FE ;

DUNKMAN, WB ;

JACOBS, W ;

FRANCIS, GS ;

FLOHR, KH ;

GOLDMAN, S ;

COBB, FR ;

SHAH, PM ;

SAUNDERS, R ;

FLETCHER, RD ;

LOEB, HS ;

HUGHES, VC ;

BAKER, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (24) :1547-1552

[18] Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril - V-HeFT III [J].

Cohn, JN ;

Ziesche, S ;

Smith, R ;

Anand, I ;

Dunkman, WB ;

Loeb, H ;

Cintron, G ;

Boden, W ;

Baruch, L ;

Rochin, P ;

Loss, L .

CIRCULATION, 1997, 96 (03) :856-863

[19] A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure [J].

Cohn, JN ;

Goldstein, SO ;

Greenberg, BH ;

Lorell, BH ;

Bourge, RC ;

Jaski, BE ;

Gottlieb, SO ;

McGrew, F ;

DeMets, DL ;

White, BG .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25) :1810-1816

[20] A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].

COHN, JN ;

JOHNSON, G ;

ZIESCHE, S ;

COBB, F ;

FRANCIS, G ;

TRISTANI, F ;

SMITH, R ;

DUNKMAN, WB ;

LOEB, H ;

WONG, ML ;

BHAT, G ;

GOLDMAN, S ;

FLETCHER, RD ;

DOHERTY, J ;

HUGHES, CV ;

CARSON, P ;

CINTRON, G ;

SHABETAI, R ;

HAAKENSON, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310

← 1 2 3 4 5 6 7 8 9 10 →